A Novel Pharmacophore Model to Identify Leads for Simultaneous Inhibition of Anti-coagulation and Anti-inflammatory Activities of Snake Venom Phospholipase A 2

Chemical Biology and Drug Design

Volumn 79, Issue 4, 2012, Pages 431-441

  Wadood, Abdul ^a,b   Ali, Syed Abid ^a   Sattar, Rabia ^a   Lodhi, Muhammad Arif ^a   Ul Haq, Zaheer ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b ABDUL WALI KHAN UNIVERSITY   (Pakistan)

Author keywords

Docking; Dual inhibitor; Pharmacophore; Phospholipase A 2; Snake; Venom; Virtual screening

Indexed keywords

INDOMETACIN; LIGAND; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; SNAKE VENOM;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; PHARMACOLOGICAL BLOCKING; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ANTIDOTES; DRUG DESIGN; MODELS, MOLECULAR; PHOSPHOLIPASES A2; SNAKE VENOMS; SNAKES;

EID: 84858792576     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01281.x     Document Type: Article

References (45)

1. 2 superfamily of signal transduction enzymes. Trends Biochem Sci;22:1-2.
2. Smith W.L., De Witt D.L., Garavito R.M. (2000) Cyclooxygenase: structural, cellular, and molecular biology. Annu Rev Biochem;69:145-182.
3. Dennis E.A. (1983) Phospholipases. In: Boyer P., editor. The Enzymes. New York: Academic Press; p. 307-353.
4. 2. J Biol Chem;262:14402-14407.
5. 2 cobra (Naja naja naja) venom. Mol Cell Biochem;219:39-44.
6. 2 from Naja nigricollis venom binds to coagulation factor Xa to inhibit the prothrombinase complex. Arch Biochem Biophys;369:107-113.
7. 2 enzymes from snake venoms. Toxicon;45:1147-1161.
8. 2 complexed with a substrate-derived inhibitor. Nature;347:689-691.
9. 2 from inflammatory exudate. Science;254:1007-1010.
10. 2) at 1.9Å resolution. Acta Crystallogr D Biol Crystallogr;D57:1793-1798.
11. 2 from common krait (Bungarus caeruleus) at 2.4Å resolution: identification and characterization of its pharmacological sites. J Mol Biol;307:1049-1059.
12. Banumathi S., Rajashankar K.R., Notzel C., Aleksiev B., Singh T.P., Genov N., Betzel C. (2001) Structure of the neurotoxic complex vipoxin at 1.4Å resolution. Acta Crystallogr D Biol Crystallogr;D57:1552-1559.
13. 2 from the venom of Deinagkistrodon acutus. Acta Crystallogr D Biol Crystallogr;D58:104-110.
14. 2. J Biol Chem;277:20059-20069.
15. 2 from the venom of Agkistrodon halys Pallas at 1.9Å resolution. Biochem Biophys Res Commun;300:271-277.
16. 2 determined from a hemihedrally twinned crystal. Acta Crystallogr D Biol Crystallogr;D59:1574-1581.
17. 2 from Indian saw-scaled viper (Echis carinatus) at 2.6Å resolution reveals a novel intermolecular interaction. Acta Crystallogr D Biol Crystallogr;D60:66-72.
18. 2 isoenzymes. FEBS J;272:1211-1220.
19. 2 inhibition for the synthesis of prostaglandins by the plant alkaloid aristolochic acid from a 1.7Å crystal structure. Biochemistry;41:10914-10919.
20. 2 and alpha-tocopherol at 1.8Å resolution. J Mol Biol;320:215-222.
21. 2 with two natural anti-inflammatory agents, anisic acid, and atropine reveal a similar mode of binding. Proteins;64:89-100.
22. 2. Nat Struct Biol;2:458-465.
23. 2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). Acta Crystallogr D Biol Crystallogr;D58:1813-1819.
24. 2 and a potent peptide inhibitor Phe-Leu-Ser-Tyr-Lys at 1.8Å resolution. J Biol Chem;277:41079-41085.
25. 2 from Naja naja sagittifera (Group I) and a designed peptide inhibitor Val-Ala-Phe-Arg-Ser (VAFRS) at 1.9Å resolution reveals unique features. Biochemistry;42:11701-11706.
26. 2 in a complex with a transition-state analogue. Science;250:1563-1566.
27. 2 and oxyphenbutazone at 1.6Å resolution. Biochemistry;43:14577-14583.
28. 2 and aspirin at 1.9Å resolution. J Drug Target;2:113-119.
29. 2 and diclofenac at 2.7Å resolution. Acta Crystallogr D Biol Crystallogr;D62:410-416.
30. 2 with niflumi acid at 2.5Å resolution. Acta Crystallogr D Biol Crystallogr;D61:1579-1586.
31. Gierse J.K., Koboldt C.M., Walker M.C., Seibert K., Isakson P.C. (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J;339:607-614.
32. Vane J.R., Botting R.M. (1998) Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med;104:2S-8S. discussion 21S-22S.
33. Vane J.R., Bakhle Y.S., Botting R.M. (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol;38:97-120.
34. 2 with anticoagulant activity. I. Isolation from Vipera berus venom and properties. Biochim Biophys Acta;429:828-838.
35. Boffa M.C., Rothen C., Verheij H.M., Verger R., DeHaas G.H. (1980) Correlation of enzymatic activity and anticoagulant properties of phospholipase A2. In: Eaker D., Walstrom T., editors. Natural Toxins. Oxford: Pergamon Press; p. 131-138.
36. 2. Eur J Biochem;112:25-32.
37. Callan O.H., So O.Y., Swinney D.C. (1996) The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J Biol Chem;271:3548-3554.
38. 2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci USA;75:2955-2958.
39. Lobo I.B., Hoult J.R. (1994) Groups I, II and III extracellular phospholipases A2: selective inhibition of group II enzymes by indomethacin but not other NSAIDs. Agents Actions;41:111-113.
40. Nygard G., Hudson M., Mazure G., Anthony A., Dhillon A.P., Pounder R.E., Wakefield A.J. (1995) Procoagulant and prothrombotic responses of human endothelium to indomethacin and endotoxin in vitro. Relevance to non-steroidal anti-inflammatory drug enteropathy. Scand J Gastroenterol;30:25-32.
41. Lyne P.D. (2002) Structure-based virtual screening: an overview. Drug Discov Today;7:1047-1055.
42. 2 complexed with indomethacin at 1.4Å resolution reveals the presence of the new common ligand-binding site. J Mol Recognit;22:437-445.
43. Wolber G., Langer T. (2005) LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model;45:160-169.
44. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. (1997) Development and validation of genetic a algorithm for flexible docking. J Mol Biol;267:727-748.
45. Labute P. (2008) The Generalized Born/Volume Integral (GB/VI) implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comp Chem;29:1693-1698.